Transplantation for multiple myeloma: Who, when, how often?

Joan Bladé, David H. Vesole, Morie Gertz

Research output: Contribution to journalReview articlepeer-review

76 Scopus citations


The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

Original languageEnglish (US)
Pages (from-to)3469-3477
Number of pages9
Issue number10
StatePublished - Nov 15 2003

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Transplantation for multiple myeloma: Who, when, how often?'. Together they form a unique fingerprint.

Cite this